Adalimumab Market to Grow with a CAGR of 4.80% through 2030
Surge in research and development activities is
expected to drive the Global Adalimumab Market growth in the forecast period,
2026-2030.
According to TechSci Research report, “Adalimumab
Market - Global Industry Size, Share, Trends, Competition Forecast &
Opportunities, 2030F”, the Global Adalimumab Market stood at USD 2.72
Billion in 2024 and is anticipated to grow with a CAGR of 4.80% through 2030. Initiatives
taken by government based on adalimumab has led to favorable market conditions
for the Global Adalimumab Market. Several factors contribute to the growth of
various adalimumab products.
One of the key areas of focus in ongoing R&D is
the development of biosimilars with improved formulations and delivery systems.
These innovations aim to enhance patient compliance by offering more convenient
dosing regimens, reduced injection site reactions, and better storage
stability. Such improvements not only increase the therapeutic appeal of
adalimumab products but also contribute to their broader adoption across
diverse patient populations. In addition, researchers are exploring the use of
adalimumab in new therapeutic indications beyond its established applications
in autoimmune conditions such as rheumatoid arthritis and Crohn’s disease.
Regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and similar agencies in other countries have streamlined approval pathways for biosimilar versions of adalimumab. These policies are designed to promote market competition, lower treatment costs, and increase therapeutic options for both physicians and patients. Several governments have also incentivized local manufacturing of biosimilars through tax benefits and grants, encouraging domestic production and reducing dependency on imports.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Adalimumab Market”
The Global Adalimumab Market is segmented into type, therapeutic
area, regional distribution, and company.
Based on Type, Biosimilars have emerged
as the dominating segment in the Global Adalimumab Market in 2024. One
of the most significant advantages of biosimilars is their ability to offer
comparable clinical efficacy and safety to the originator product at a fraction
of the cost. This affordability has made biosimilars increasingly attractive to
healthcare providers, insurance payers, and patients, especially in regions
where the high cost of biologics has historically limited access to advanced
treatments. As a result, the adoption of biosimilar adalimumab has accelerated
across both developed and emerging markets.
Based on Region, Asia Pacific have emerged as the fastest
growing region in the Global Adalimumab Market in 2024. The region has
witnessed a significant rise in the incidence of conditions such as rheumatoid
arthritis, psoriasis, and inflammatory bowel disease, all of which are commonly
treated with adalimumab. This growing disease burden, combined with improved
diagnostic capabilities, is contributing to heightened demand for advanced
biologic treatments. In addition, governments across countries like China,
India, and South Korea are increasing healthcare spending and implementing
supportive policies to enhance access to biologics, including the approval and
distribution of adalimumab biosimilars.
Major companies operating in Global Adalimumab Market
are:
- AbbVie Inc.
- Pfizer, Inc.
- Amgen Inc.
- Novartis AG
- Torrent Pharmaceuticals Ltd.
- Cadila Healthcare Limited
- Boehringer Ingelheim International GmbH
- Mylan N.V.
- Hetero Biopharma Ltd
- Samsung Bioepis Co Ltd.
Download Free Sample Report
Customers can also request for 10% free
customization on this report
“The integration of nanotechnology in the global
adalimumab market is emerging as a transformative advancement, offering
promising solutions to enhance the efficacy, stability, and delivery of
adalimumab-based therapies. Nanotechnology-based drug delivery systems, such as
nanoparticles, liposomes, and nanoemulsions, are being explored to improve the
pharmacokinetic profile of adalimumab, ensuring more targeted delivery and
sustained release at the site of inflammation. This approach not only minimizes
systemic side effects but also enhances therapeutic outcomes, particularly in
chronic autoimmune conditions like rheumatoid arthritis and Crohn’s disease”,
said Mr. Karan Chechi, Research Director of TechSci Research, a research-based
management consulting firm.
“Adalimumab Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Biologics, Biosimilars), By Therapeutic Area (Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis, Crohn’s Disease, Others), By Region and Competition, 2020-2030F”, has evaluated
the future growth potential of Global Adalimumab Market and provides statistics
& information on market size, structure, and future market growth. The
report intends to provide cutting-edge market intelligence and help decision
makers take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in Global Adalimumab Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com